On 28 January, Alector, a biotechnology company developing immuno-neurology therapies for the treatment of neurodegenerative diseases, announced the dosing of the first participants with Alzheimer’s disease (AD) in its Phase Ib trial of AL003. “We have developed AL003 to block the inhibitory function of SIGLEC 3, an immune receptor linked to Alzheimer’s disease. AL003 is intended to allow the brain’s immune system to simultaneously address multiple parallel pathologies involved in the progression of Alzheimer’s disease,” said Arnon Rosenthal, Chief Executive Officer of Alector.
The Phase Ib trial named INTERCEPT is a multi-center, randomised, double-blind and placebo-controlled study evaluating the safety and tolerability of AL003. Approximately 12 research participants with mild to moderate AD will be enrolled to receive multiple-doses of AL003 by intravenous infusion. The company reported that tolerable doses were found in healthy research participants.
